BioSig Technologies Inc. (Nasdaq: BSGM) in its US$770-million business combination with Streamex Exchange, a commodities tokenization platform
MustGrow Biologics in its acquisition of NexusBioAg, which provides crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, and foliar products, from Univar Solutions Canada
Briacell Therapeutics Corp., in its public offering of common shares for gross proceeds of USD$3,050,000
Medicus Pharma Ltd., in its acquisition of Antev Limited, a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention episodes due to enlarged prostate, for consideration of up to approximately US$75 million.
Medicus Pharma Ltd., (TSXV: MDCX; NASDAQ: MDCX), in its US IPO and NASDAQ-listing
Numinus Wellness Inc., in the establishment of a shelf prospectus for proceeds of $150M.
Bloom Burton & Co. and Haywood Securities Inc. in a US$150-million private placement of common shares of Cybin Inc.
Reunion Neuroscience Inc., in its take-private transaction with MPM Bioimpact.
A.G.P./Alliance Global Partners, in a US$30-million public offering of units pursuant to a prospectus supplement with Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).
TerrAscend Corp., in its arrangement with Canopy USA, LLC to convert $125.5M in debt to securities.
Field Trip Health Ltd., in the spin-out of its drug development and medical clinics businesses into two independent public companies, Reunion Neuroscience and Field Trip Health & Wellness, by plan of arrangement. The spin-out transaction was supported by a private placement financing led by Oasis Management Company.
Cantor Fitzgerald Canada Corporation, in an up to US$35-million at-the-market equity program for the sale of common shares pursuant to an equity distribution agreement with Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).
MustGrow Biologics Corp., in connection with the filing of a base shelf prospectus relating to the offering for sale, from time to time, of common shares, warrants, units, debt securities, subscription receipts or any combination thereof for aggregate gross proceeds of up to $40 million
Wellfield Technologies Inc., in its acquisition of New Bit Ventures Ltd., d/b/a Coinmama at an agreed valuation of US$50 Million
Cresco Labs Inc. in its US$2-billion acquisition of Columbia Care Inc., making Cresco the second-largest cannabis producer and retailer in the U.S. at the time of the transaction.
VIVO Cannabis Inc. in its $133-million acquisition of Canna Farms Limited.
Cresco Labs, LLC in its US$125-million offering of subordinate voting shares.
Seamless Logic Software Limited, in its merger with MoneyClip Inc. to create Wellfield Technologies Inc., and the listing of Wellfield on the TSX Venture Exchange which was supported by a $20-million financing, bringing the total post-money valuation of Wellfield to >$100-million.
MustGrow Biologics Corp., in its non-brokered private placement for gross proceeds of $7.1-million.
ATB Capital Markets Inc. in the $7.14-million private placement offering of The Flowr Corporation.
48North Cannabis Corp. in its $50-million acquisition by HEXO Corp.
Cantor Fitzgerald Canada Corporation, in an up to $30-million at-the-market equity program for the sale of common shares pursuant to an equity distribution agreement with Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF).
A syndicate of underwriters, led by Cantor Fitzgerald Canada Corporation, in the $15.9-million bought deal short form prospectus offering of The Flowr Corporation.
A syndicate of underwriters, led by Cantor Fitzgerald Canada Corporation, in the $22.7-million bought deal offering of units of Aleafia Health Inc.
A syndicate of underwriters, led by Cantor Fitzgerald Canada Corporation, in the $33.4-million bought deal equity financing of units of MediPharm Labs Corp.
Cresco Labs, in its US$207-million acquisition of Bluma Wellness Inc. a vertically integrated operator in Florida.
PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.), in a $14.5-million reverse takeover of PsyBio Therapeutics, Inc., a biotechnology company developing a new class of drugs intended for the potential treatment of mental health challenges and other disorders.
TerrAscend Corp., in its C$224-million non-brokered private placement with 80% of commitments from four large US institutional investors including Wasatch Global.
Blog
Blog
Blog
